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Background: 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a commercial chemotherapeutic 
drug for treating malignant brain tumors, has poor thermal stability and a short half-life. 
Immobilization of BCNU on a nanocarrier might increase the thermal stability of BCNU and 
extend its half-life.
Methods: Nanosized graphene oxide (GO) could be modified by polyacrylic acid (PAA) to 
improve the aqueous solubility and increase the cell penetration efficacy of the nanocarrier. 
PAA–GO intended as a drug carrier for BCNU was prepared and characterized in this study. 
The size and thickness of PAA–GO was investigated by transmission electron microscopy and 
atomic force microscopy, and the presence of PAA functional groups was confirmed by electron 
spectroscopy for chemical analysis and thermogravimetric analysis. BCNU was conjugated to 
PAA–GO by covalent binding for specific killing of cancer cells, which could also enhance 
the thermal stability of the drug.
Results: Single layer PAA–GO (about 1.9 nm) with a lateral width as small as 36 nm was 
successfully prepared. The optimum drug immobilization condition was by reacting 0.5 mg 
PAA–GO with 0.4 mg BCNU, and the drug-loading capacity and residual drug activity were 
198 µg BCNU/mg PAA–GO and 70%, respectively. This nanocarrier significantly prolonged 
the half-life of bound BCNU from 19 to 43 hours compared with free drug and showed efficient 
intracellular uptake by GL261 cancer cells. The in vitro anticancer efficacy of PAA–GO–BCNU 
was demonstrated by a 30% increase in DNA interstrand cross-linking and a 77% decrease in 
the IC50 value toward GL261 compared with the same dosage of free drug.
Conclusion: Nanosized PAA–GO serves as an efficient BCNU nanocarrier by covalent binding. 
This nanocarrier will be a promising new vehicle for an advanced drug delivery system in 
cancer therapy.
Keywords: graphene oxide, BCNU, glioma cells, drug delivery, thermal stability
Introduction
In recent years, advanced drug-delivery systems have improved cancer therapy out-
comes with great promise.1 Development of different nanoscale drug carriers has been 
an important focus in advanced drug-delivery systems.2–4 Some recently approved 
advanced drug-delivery systems, like liposomes and/or polymer nanoparticles, have 
led to many obsolete drugs regaining the possibility of clinical use.5 An ideal advanced 
drug-delivery system includes controlled release (triggered release of drug under a 
characteristic environment of diseased cells) and drug protection until entering diseased 
cells, which aim to prevent early drug degradation and to increase the intracellular 
drug concentration.6 By using this system for drug delivery, we can not only improve 
treatment efficacy, but also decrease systemic toxicity.
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Since 2004, “graphene”, a novel two-dimensional hon-
eycomb material, has been recognized as one of the most 
promising materials used as a filler in polymer matrices. 
Graphene can enhance the mechanical strength, conductivity, 
and gas barrier performance of composite materials due 
to its high intrinsic mobility, high thermal conductivity, 
mechanical stiffness, excellent electrical conductivity, and 
good gas barrier properties.7,8 This versatile material has 
also found many applications in biological systems, such 
as drug delivery, gene delivery, and biosensors in the past 
two years.9–11 Compared with other carrier materials used in 
advanced drug-delivery systems, graphene oxide (GO) offers 
a high surface to weight ratio, high possibility for surface 
modification, high drug-loading efficiency, a pH-responsive 
drug-delivery mechanism, and photothermal effects.12,13 
Furthermore, it has been demonstrated that functionalized 
GO can enter mammalian cells, which renders it a reason-
able drug carrier.9 Unlike the common poor water dispersion 
problem faced by other carbon nanomaterials, like fullerenes 
and carbon nanotubes, pristine GO has good aqueous solubil-
ity because of abundant hydrophilic groups on both sides of 
its large surface. The hydrophilic groups include hydroxyl, 
epoxide, and carboxylic groups. These functional groups help 
to maintain stability in physiological solutions and increase 
the ability to carry drugs.14
Brain malignancy is notorious for its high recurrence 
and mortality rate, although its prevalence is relatively low 
compared with other forms of cancer. Most malignant brain 
tumors in adults are glioblastoma multiforme (GBM).15 
GBM is a highly invasive tumor originating from glial 
cells with indistinct borders along the normal parenchyma, 
and is difficult to remove by surgical excision. The median 
survival of GBM patients is approximately one year.16 The 
dismal prognosis and limited treatment choices give rise 
to the need for a novel and more efficient delivery route 
for chemotherapy against GBM. 1,3-bis(2-chloroethyl)-
1-nitrosourea (BCNU) is a commercial chemotherapeutic 
drug for brain malignancy because of its ability to penetrate 
the blood–brain barrier. The limitation to the clinical use 
of BCNU is its severe side effects, including bone marrow 
suppression, hepatotoxicity, and pulmonary fibrosis.17 In 
addition, metabolism in the liver after intravenous injection 
leads to transformation of BCNU into an active form before 
entering the brain tumor. To increase its usability, new forms 
of advanced drug-delivery systems have been developed for 
BCNU over the years. The most widely used delivery route in 
clinical practice is a BCNU wafer put on the tumor bed after 
surgery. Through gradual degradation of the matrix polymer, 
BCNU is released into the peripheral brain parenchyma up 
to 2 cm in depth.18
Currently, all the methods used to bind drugs on GO are 
based on noncovalent interactions. For example, π–π stacking 
prevails between GO and chemotherapeutic drugs possessing 
aromatic ring structures, such as doxorubicin, camptothecin, 
and SN-38. This adsorption binding method provides GO 
with a high drug-loading efficiency due to its high surface/
volume ratio for drug loading.19 Dai et al explained that 
PEGylated GO can carry water-insoluble cancer drugs such 
as camptothecin and SN38 and showed pH-dependent drug 
release behavior.9 Chen et al used a chemical coprecipitation 
method to add Fe3O4 magnetic nanoparticles onto graphene. 
After decorating with folic acid as a targeting ligand, the 
drug-loaded graphene selectively killed breast cancer cells 
with released doxorubicin.12 Tan et al modified graphene 
with polyvinyl alcohol for adsorption of doxorubicin to treat 
breast cancers cells.20 Zhang et al increased pH-responsive 
drug-releasing ability by adding sulfonic acid on graphene. 
GO carried more than 40% doxorubicin and 4.5% camptoth-
ecin in weight ratio and released 35% doxorubicin and 17% 
camptothecin at pH 5.0.21 In another study, Zhang et al added 
polyethylenimine onto graphene to adsorb SiRNA. The posi-
tive charged polyethylenimine could attract SiRNA which is 
abundant with negative charged moiety. The drug resistance 
rate decreased through inhibited production of Bcl-2 protein 
by SiRNA and the cytotoxic efficacy of the doxorubicin on 
graphene increased.22 Similarly, Gan et al adsorbed plasmid 
DNA on chitosan-decorated graphene to increase the cyto-
toxic effect of camptothecin by DNA integration.23
As shown from previous discussion of up-to-date inves-
tigations using GO as a nanocarrier for anticancer drugs, the 
most popular drug-loading method is noncovalent binding. 
However, for an anticancer drug without aromatic ring struc-
tures, such as BCNU, π–π stacking force will be weak and 
the most suitable method for drug loading may be covalent 
binding. To date, there have been no articles describing this 
alternative drug-loading method for GO, which will widen 
the application of GO in drug or gene delivery. In this work, 
we first modified the GO surface with abundant polyacrylic 
acid (PAA) chains. PAA is a biocompatible material showing 
mucus-adhesive characteristics, which can enhance the solu-
bility and dispersibility of GO in biological solutions without 
decreasing its high drug-loading ability.24 The carboxyl 
groups of PAA can react with BCNU through carbodiimide-
mediated amide bond formation to increase drug loading 
(Figure 1). To our best knowledge, this is the first paper 
describing covalent binding of a chemotherapeutic agent 
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without aromatic structures. The results revealed excellent 
IC50 in killing malignant GL261 glioma cells. The thermal 
stability of PAA–GO–BCNU and cell apoptosis through an 
interstrand DNA cross-linking mechanism to validate this 
novel drug carrier was also studied.
Materials and methods
Materials
The raw materials of graphite platelet (model xGnP) mea-
suring 100 µm in width and 5–15 nm in thickness were 
obtained from XG Sciences Inc (East Lansing, MI). Acrylic 
acid, potassium persulfate, sulfuric acid (H2SO4, 98%), 
sodium sulfate (Na2SO4), potassium permanganate (KMnO4), 
hydrogen peroxide solution (H2O2), and ammonia solution 
were purchased from Showa Chemical Co (Tokyo, Japan). 
BCNU was obtained from Boehringer Ingelheim (Mannheim, 
Germany). GL261 glioma cells were obtained from Professor 
Chia-Rui Shen at the Graduate Institute of Medical Biotech-
nology (Chang Gung University, Taiwan). Hank’s balanced 
salt solution and RPMI-1640 were bought from Gibco (Grand 
Island, NY). Fetal bovine serum was bought from Biological 
Industries (Beit-Haemek, Israel). Gentamicin, penicillin, and 
streptomycin were obtained from MDBio. A LIVE/DEAD 
viability/cytotoxicity kit and minimum essential medium 
were bought from Invitrogen (Carlsbad, CA).   Glutaraldehyde, 
1-ethyl-3-(3-dimethylaminepropyl) carbodiimide hydrochlo-
ride (EDC), 2-(N-morpholino)ethanesulfonic acid hydrate 
(MES), sulfanilamide, and N-hydroxysulfosuccinimide 
sodium salt (sulfo-NHS) were purchased from Sigma 
(St Louis, MO). Deionized water was used in all experiments. 
All reagents were of analytical grade and used without any 
further purification.
Preparation of GO
Preparation of GO followed the modified Hummers’ 
method.25 Two hundred fifty milligrams of graphite platelet, 
0.125 g NaNO3, and 12 mL of H2SO4 (98%) were added into 
a 100 mL flask in an ice bath under magnetic stirring. Next, 
0.75 g KMnO4 was added slowly to the solution while keeping 
the temperature below 5°C. After adding KMnO4, the ice bath 
was removed and the flask was heated to 100°C, followed by 
slow addition of 12 mL of deionized water. The temperature 
of the solution was increased to 98°C and the solution was 
maintained at this temperature for 30 minutes. Next, 50 mL of 
deionized water with 10% H2O2 was added to the solution until 
the cessation of gas evolution. The solution was centrifuged at 
11,000 rpm and washed using deionized water several times to 
remove impurities. The precipitate was collected and subject 
to ultrasonication for 8 hours at 800 W using an Ultrasonic 
Liquid Processor 2020 from Misonix (Farmingdale, NY) and 
centrifugation at 10,000 rpm for 3 hours. The supernatant was 
collected and filtered with Acrodisc 25 mm syringe filters 
(0.2 µm Supor membrane) three times, and the GO collected 
in the filtrate was subjected to further modification.
HOOC
HOOC
OH
O
COOH
O
H
O
O
O
HOOC
HOOC
OH
O
COOH
O
H
O
O
O
GO
PAA−GO−BCNU
PAA−GO
Free radical
BCNU loading by
covalent binding
of 2-chloroethanediazonium ions
Intracellular uptake and release
polymerization
BCNU
Poly(acrylic acid)
Active site
Active site: 2-chloroethanediazonium ions
Covalent site: binding with −COOH on PAA−GO
Covalent site
Nucleus
C
Cl Cl
O
O
N
N
N
H
C
O
HO
H C
H2
n
Figure 1 a schematic diagram showing synthesis of Paa–GO from GO, conjugation of BCNU to Paa–GO by covalent binding, delivery of Paa–GO–BCNU to cancer 
cells, and the cytotoxic effect of BCNU.
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea.
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Preparation of Paa–NGO
PAA-grafted GO (PAA–GO) was synthesized by free radical 
polymerization. In a typical experiment, 0.1 g GO and 40 mL 
H2O were added into a 100 mL four-necked flask. After 
low-energy ultrasonication (12 W, 55 kHz, 30 minutes), the 
flask was stirred in a thermostatic oil bath at 50°C under a 
nitrogen atmosphere. Then, a well-mixed solution of 15 mg 
potassium persulfate dissolved in 2 g acrylic acid monomers 
was added through a tube pumped at a rate of 0.5 mL/minute. 
The free radical polymerization reaction was initiated by 
potassium persulfate, which was continued for 8 hours. After 
polymerization, the solution was centrifuged at 11,000 rpm 
and washed using deionized water several times to remove 
the impurities and reactants. The above steps were repeated 
5–6 times to remove unreacted acrylic acid completely and 
the product was dried in a vacuum oven at 80°C overnight 
to remove the solvent, after which PAA–GO in the form of 
a black powder was obtained.
Characterization of GO and Paa–GO
An atomic force microscope (XE-100; PISA, Santa Clara, 
CA) was used to analyze the surface topography and size of 
the nanocarrier. Diluted GO and PAA–GO in alcohol were 
deposited onto a freshly cleaved mica substrate and imaged 
after alcohol evaporation. Experiments were performed with 
a tapping mode and all images were recorded in air at room 
temperature at 256 pixels, with a scan size of 0.5 × 0.5 µm2 
and a scan speed of 0.9 Hz. GO and PAA–GO were subject to 
X-ray photoelectron spectroscopy analysis using a ESCALAB 
220 iXL (VG Scientific, East Grinstead, UK) spectrometer 
equipped with a hemispherical electron analyzer and a Mg K 
(hv = 1487.7 eV) X-ray source. A small spot lens system was 
needed to analyze a sample less than 1 mm2 in area. The PAA 
content of PAA–GO was determined by thermogravimetric 
analysis using an STA 449 PC from Netzsch. Analysis was 
performed with 20 mg of samples in a platinum pan under 
nitrogen atmosphere. The nominal gas flow was 5 mL/minute, 
and the heating velocity was 20°C/minute.
Immobilization of BCNU on Paa–GO
The BCNU was dissolved in a 70:30 (v/v) mixture of deion-
ized water and ethanol with a concentration of 10 mg/mL. 
A 0.1 mL aliquot of EDC solution (12 mg/mL EDC in 0.5 M 
MES buffer, pH 6) was mixed with 0.1 mL of PAA–GO 
(5 mg/mL) at 25°C and sonicated for 20 minutes in the dark 
at room temperature. After separation with centrifugation 
at 7000 rpm for 7 min, PAA–GO was washed twice using 
0.5 mL of deionized water, resuspended in 0.2 mL of 0.1 M 
MES buffer, and mixed with 0.2 mL BCNU of different 
concentrations at 10°C. The solutions were mixed by soni-
cation for 0.5 hours and then shaken for another 1.5 hours 
at 10°C. PAA–GO with BCNU immobilized on the surface 
were separated from the solution using centrifugation, washed 
with pure alcohol and deionized water, washed again with 
deionized water to remove residual alcohol, and dispersed 
in 0.1 mL of deionized water.26 To calculate the ratio of 
BCNU immobilized on PAA–GO (ie, PAA–GO–BCNU), 
the supernatant was analyzed by high-performance liquid 
chromatography on a SUPELCOSIL LC-18 column 
(4.6 × 250 mm) using a L-2130 pump and a L-2400 ultra-
violet detector (Hitachi, Tokyo, Japan). The mobile phase 
was a 40:60 (v/v) mixture of deionized water and methanol 
with a flow rate of 2 mL/minute. The absorbance data were 
obtained at 270 nm.
Thermal stability study of BCNU
The stabilities of free BCNU and PAA–GO–BCNU at 
1 mg/mL BCNU were tested by incubation at 37°C for 
up to 14 days. The drug activities were analyzed using 
the Bratton–Marshall assay.27,28 Forty microliters of free 
BCNU and PAA–GO–BCNU solution were reacted with 
80 µL of sulfanilamide solution (5 mg/mL in 2 M HCl) at 
50°C for 45 minutes and then cooled to room temperature. 
One hundred microliters of the above solution and 10 µL of 
Bratton–Marshall reagent (3 mg/mL of N-(1-naphthyl) ethyl-
enediamine in deionized water) were reacted for one minute 
and absorbances were measured at 540 nm using a Genesys 
20 spectrophotometer (Thermo Scientific, Barrington IL).
Cellular uptake study
To prepare fluorescent PAA–GO, EDC 12 mg and sulfo-NHS 
27 mg were dissolved in 2 mL of 0.5 M MES buffer (pH 6.3) 
in the dark. A 0.2 mL aliquot of the above solution was mixed 
with 0.2 mL of PAA–GO (5 mg/mL) at 25°C and reacted for 
30 minutes in the dark. After separation and washing with 
deionized water, activated PAA–GO was added to 0.2 mL 
of MES buffer, mixed with 0.1 mL of the monofunctional 
hydrazide cyanine 5 (Cy5) at 25°C, and then vortexed for 
2 hours in the dark. The PAA–GO with Cy5 immobilized 
on the surface (PAA–GO–Cy5) were separated from the 
solution and washed with deionized water. GL261 cells 
were cultured in RPMI-1640 supplemented with 2.2 mg/mL 
sodium carbonate, 10% fetal bovine serum, 50 µg/mL gen-
tamicin, 50 µg/mL penicillin, and 50 µg/mL streptomycin 
at 37°C and 5% CO2. Approximately 2 mL of GL261 cells 
(10,000 cells/mL) were plated in 35 mm diameter plates and 
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cultured in a humidified chamber at 37°C and 5% CO2 for 
48 hours. PAA–GO–Cy5 in 100 µL of minimum essential 
medium were added, and the incubation was continued for 
6 hours. The medium was removed, and the cells were washed 
with 1 mL of Hank’s balanced salt solution and then fixed 
with fresh ethanol on ice for 5 minutes at room temperature. 
The cells were washed three times with Hank’s balanced salt 
solution and analyzed on a TCS SP2 confocal microscope 
(Lecia, Wetzlar, Germany).
For transmission electron microscopic observation, 
GL261 cells were grown to 50%–60% confluence on 
Thermonax coverslips and treated with PAA–GO for 2 hours, 
followed by washes in phosphate-buffered saline and addi-
tional incubation in fresh media for 1 hour. Next, the cells 
were fixed in a mixture of 2.5% paraformaldehyde and 2.0% 
glutaraldehyde in phosphate-buffered saline for 30 minutes 
followed by extensive washes in phosphate-buffered saline. 
Then the cells were rinsed in 0.1 M sodium cacodylate 
buffer (pH 7.4) and postfixed in 1.0% osmium tetroxide in 
the above buffer for 30 minutes. After several rinses in the 
sodium cacodylate buffer, the samples were dehydrated in a 
series of ethanol solutions (20%, 40%, 60%, 75%, and 95% 
for 5 minutes and 100% for 30 minutes with three changes) 
and infiltrated with Epon-Araldite (Ted Pella, Redding, CA) 
for 2 days (25% Epon-Araldite and ethanol for 2 hours, 
50% for 4 hours, 75% for overnight, and 100% for 1 day, 
with two changes). Samples were polymerized at 60°C for 
2 days. Next, ultrathin sections (approximately 80 nm) were 
cut on a Reichert Ultracut E Microtome (American Optical, 
Buffalo, NY) and collected on film-supported slot grids. 
Sections were lightly counterstained with uranyl acetate and 
lead citrate, and examined under a FEI CM120 transmission 
electron microscope equipped with a Gatan GIF100 image 
filter and operated at a beam energy of 120 keV .
DNA cross-linking test
The ethidium bromide fluorescence assay29 was used to 
measure the level of DNA cross-linking caused by BCNU in 
GL261 cells. The cells were exposed initially to different con-
centrations (5–30 µg/mL) of free BCNU or PAA–GO–BCNU 
and incubated for 12 hours. After incubation, about 1 × 106 
cells were collected by centrifugation at 5000 rpm for 
5 minutes at 8°C and resuspended in phosphate-buffered 
saline. Forty microliters of the cell suspension were incubated 
for 15 minutes at 4°C with 200 µL of lysis buffer. After lysis, 
the cell pellets were separated by centrifugation at 5000 rpm 
for 6 minutes and the suspension was incubated with 25 µL 
of heparin (500 IU/mL) for another 20 minutes at 37°C, 
followed by addition of 1 mL of ethidium bromide solution. 
The mixture was heated for 5 minutes at 100°C to denature 
the DNA, then cooled in an ice bath for 6 minutes to renature 
it. Fluorescence was measured with excitation and emission 
wavelengths of 525 nm and 580 nm, respectively.
In vitro anticancer efficacy
GL261 cells were cultured in RPMI-1640 supplemented 
with 2.2 mg/mL sodium carbonate, 10% fetal bovine serum, 
50 µg/mL gentamicin, 50 µg/mL penicillin, and 50 µg/mL 
  streptomycin at 37°C and 5% CO2. Approximately 10,000 cells 
were placed in each well of a 96-well culture plate and 
incubated in a humidified chamber at 37°C and 5% CO2 for 
24 hours. Free BCNU and PAA–GO–BCNU (BCNU concen-
tration 0–100 µg/mL) were added to the medium and the cul-
ture continued. Cell growth was observed by counting the cells 
after 24 and 48 hours. Before counting, the culture medium was 
removed and cells were incubated in 120 µL of XTT solution 
for 3 hours. After the reaction, 100 µL of XTT solution was 
sampled from each well and transferred to a 96-well counting 
dish. Cytotoxicity toward GL261 cells in vitro was evaluated 
by measuring the optical density at 490 nm using an enzyme-
linked immunosorbent assay reader. In a separate series of 
experiments, 2 mL of GL261 cells (10,000 cells/mL) were 
plated in 35 mm diameter plates and cultured in a humidified 
chamber at 37°C and 5% CO2 for 72 hours. Free BCNU and 
PAA–GO–BCNU (BCNU concentration 0, 2, 5, 10 µg/mL) 
in 100 µL of culture medium were added and the incubation 
continued for 12 hours. The medium was removed, the cells 
were washed with 1 mL of Hank’s balanced salt solution, and 
1 mL of LIVE/DEAD reagent was added. After 30 minutes, 
the reagent was removed and the cells were washed again with 
Hank’s balanced salt solution. Cytotoxicity was monitored 
using a Leica TCS SP2 confocal microscope.
Results and discussion
Characterization of Paa–GO
The nanocarrier were prepared using a modified Hummer 
method and followed by long-term ultrasonication to obtain 
nanosized GO. After ultrasonication treatment, the lateral 
width of GO were shortened from several hundred nanome-
ters to be less than 50 nm, but still remained single-layered 
(about 1 nm), as shown by atomic force microscopy images 
(Figure 2A). Next PAA was grafted onto GO to form PAA–
NGO via free radical polymerization. The morphology of 
PAA–NGO observed by atomic force microscopy exhibited 
similar lateral widths with GO, indicating that the dimension 
of GO and PAA–GO were almost the same. The thicknesses 
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of PAA–GO increased from 0.9 nm to 1.9 nm after grafting 
PAA chains onto the GO surface (Figure 2B). Controlling the 
dimensions of PAA–GO to within 2 × 40 nm is very helpful 
for their efficient intracellular uptake into cells.11 Moreover, no 
contaminating particles appeared on the surface of both GO 
and PAA–GO, revealing great purity of these two materials. 
PAA–GO also showed excellent dispersibility and did not 
agglomerate after storage in water for several months.
Because different structural forms of carbon exhibit 
different oxidation behaviors, thermogravimetric analysis 
is a powerful tool for investigating the thermal stability of 
the graphene-based materials and the thermal stability of 
surface-functionalized GO materials. The compositions 
of GO and PAA–GO were studied by thermogravimetric 
analysis and the results are shown in Figure 3. The thermo-
gravimetric analysis thermograms of both samples showed a 
small weight loss (,5 wt%) at low temperature (,200°C), 
which can be attributed to loss of absorbed water and decom-
position of   oxygen-containing functional groups. However, 
within the temperature range from 200°C to 250°C, the 
  thermogravimetric analysis curve of GO indicated a much 
smaller mass loss compared with PAA–GO, and PAA–GO 
showed a maximum weight loss at 235°C from the derivative 
weight loss curve (Figure 3). This phenomenon corresponded 
with the thermal decomposition of the PAA polymer backbone. 
When the temperature further increased (.300°C), weight loss 
of both GO and PAA–GO could be attributed to the decom-
position of GO. By calculating the weight loss percentage of 
PAA–GO from 200°C to 250°C, it could be estimated that the 
content of PAA in PAA–NGO was about 16.7%.
X-ray photoelectron spectroscopy was used further to 
analyze the surface composition and structure of GO and 
PAA–GO by providing information of core-level bind-
ing energy, and to detect the functional groups present on 
PAA–GO based on chemical shifts. The C1s core level spectra 
of GO are presented in Figure 4A, which shows two major 
peaks (284.0 eV and 284.9 eV) attributing to the graphitic 
structure.30 Figure 4B shows additional peaks at higher bind-
ing energies for PAA–GO, indicating the presence of carbon 
atoms in other functional groups. The additional X-ray photon 
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Figure 2 atomic force microscopic images of (A) GO, and (B) Paa–GO.
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid.
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spectroscopy peaks of PAA–GO, appearing at 285.1 eV and 
285.7, originate from the PAA main chain structure.31,32 The 
presence of these structure and functional group agrees well 
with the expected surface structure of PAA–GO. Furthermore, 
x-ray photon spectroscopy results of PAA–GO show that the 
PAA main chain structure and the –COOH functional group 
have a 1:1 peak ratio, providing clear evidence that GO has 
been successfully grafted with PAA.
Quantification and stability  
of Paa–GO–BCNU
To be an effective therapy, BCNU must be efficiently 
  immobilized on the surface of the PAA–GO to provide 
an effective therapeutic dose without requiring repeated 
  injection of PAA–GO–BCNU, thus alleviating the side 
effects of BCNU. As shown in Figure 5A, the drug-loading 
capacity increased with the amount of BCNU used in the 
conjugation reaction, and reached a plateau when $0.4 mg 
BCNU was used, with the maximum loading capacity being 
about 200 µg BCNU/g PAA–GO. On the contrary, drug 
activity decreased with the amount of BCNU used in the 
conjugation reaction due to steric hindrance and/or structural 
changes, and leveled off at 65% when $0.4 mg BCNU was 
used. Considering both drug-loading capacity and activity, 
0.4 mg BCNU was deemed to be the optimum condition to 
react with 0.5 mg PAA–GO for immobilization of BCNU, 
where the drug-loading capacity and activity are 198 µg 
BCNU/mg PAA–GO and 70%, respectively.
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BCNU has poor thermal stability and a short half-life, 
and its hydrolysis rate was reported to increase with increas-
ing temperature, resulting in a failure to crosslink DNA.33 
Immobilization of BCNU to a nanocarrier might offer addi-
tional advantages compared with free drug by increasing 
the thermal stability of BCNU. Indeed, the hydrolysis rate 
of BCNU was decreased after conjugation onto the surface 
of PAA–GO, which resulted in an increased half-life from 
19 hours to 43 hours compared with free BCNU (Figure 5B). 
The improvement could have arisen from the immobiliza-
tion of BCNU onto PAA–GO through covalent binding, 
which protects drug conformation, prevents distortion of its 
molecular structure, and then extends the half-life of drug 
activity.34 Therefore, PAA–GO is expected to protect BCNU 
better from nonspecific hydrolysis, which can preserve the 
release of active 2-chloroethanediazonium ions and the DNA 
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Figure 5 (A) Drug-loading capacity (■) and residual drug activity (●) of BCNU immobilized to Paa–GO. (B) Relative stability of free BCNU (■) and Paa–GO–BCNU (●) 
at 37°C where activities at day 0 were taken as 100% for free BCNU and Paa–GO–BCNU, respectively.
Note: Values are the mean ± standard deviation (n = 6).
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea.
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Figure 6 (A and B) Transmission electron micrographs of Gl261 cells cocultured with Paa–GO. (C) Fluorescence micrographs of Gl261 cells cultured with Paa–GO–Cy5.
Notes: Phase image (left), fluorescence image (middle), merged image (right). (A) Bar = 500 nm, (B) bar = 100 nm, (C) bar = 5 µm.
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid.
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Figure 7 Viability of Gl261 cells after incubation for 48 hours with Paa–GO (0–200 µg/ml) and assayed by the MTT method by measuring absorbance at 570 nm (OD570). 
Note: Values are the mean ± standard deviation (n = 6).
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid.
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Figure 8 (A) Viability of Gl261 cells after incubation for 24 hours with free BCNU (■), Paa–GO–BCNU (▲); for 48 hours with free-BCNU (●), Paa–GO–BCNU (▼). 
(B) DNa interstrand crosslinking in Gl261 cells after treatment 12 hours with free BCNU (■) and Paa–GO–BCNU (●).
Note: Values are the mean ± standard deviation (n = 5).
Abbreviations: GO, graphene oxide; Paa, polyacrylic acid; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea.
cross-linking ability of BCNU after intracellular uptake of 
PAA–GO–BCNU to ensure a higher effective drug dosage 
toward cancer cells (Figure 1).
Cellular uptake of Paa–GO
All eukaryotic cells continuously ingest parts of their plasma 
membranes via endocytosis. Endocytotic vesicles are 
generated when segments of the plasma membrane invagi-
nate, enclosing extracellular substances. Most endocytotic 
vesicles fuse with primary lysosomes to form secondary 
lysosomes that contain hydrolytic enzymes and act as spe-
cialized organelles for intracellular disposal.35 Internalization 
of PAA–GO by GL261 cells was observed by transmission 
electron microscopy. Intracellular uptake was evident after 
contacting PAA–GO with cells for 6 hours, which are found 
within endosomes in the cytoplasmic region (Figure 6A). 
The presence of PAA–GO in close proximity to the nuclear 
region can be also observed (Figure 6B). The intracellular 
PAA–GO was also investigated by culture of GL261 cells with 
PAA–GO–Cy5 for 6 hours (Figure 6C). Indeed, PAA–GO 
(red color) could be detected within the cytoplasm of cells. 
In vitro confocal and transmission electron microscopic 
images therefore strongly support efficient entry of PAA–GO 
into cancer cells, which could potentially enhance the apop-
totic effects of immobilized BCNU via efficient endocytic 
pathway and raise the effective intracellular drug activity.34
In vitro anticancer efficacy
The cytotoxicity of PAA–GO–BCNU toward GL261 cells 
was determined using the XTT assay. In control experiments, 
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cells cultured with PAA–GO for 48 hours remained fully 
viable, indicating that the nanocarrier does not have any 
toxic effect toward GL261 cells (Figure 7). In contrast, free 
BCNU and PAA–GO–BCNU were toxic to GL261 cells in a 
  concentration-dependent manner. The IC50 (ie, the concentra-
tion required for 50% inhibition of cellular growth after incu-
bation for 48 hours) of PAA–GO–BCNU was 18.2 µg/mL, 
which was only 23% that of free BCNU (78.5 µg/mL, 
Figure 8A). The anticancer activity shown by BCNU is 
related to its ability to induce DNA interstrand cross-linking 
as the 2-chloroethanediazonium ions produced by BCNU 
binds to guanine residues of DNA at the O6-position to 
form O6-(2-chloroethyl)deoxyguanosine and kill the cells.36 
Hence, the extent of DNA cross-linking was also used to 
determine the anticancer efficacy of PAA–GO–BCNU. The 
occurrence of interstrand cross-linking was about 15.5% 
after treatment with 40 µg/mL of free BCNU for 12 hours 
but increased approximately 1.3-fold to 19.6% using the same 
concentration of PAA–GO–BCNU (Figure 8B). This higher 
level of interstrand cross-linking correlated with increased 
cytotoxicity.
Fluorescence microscopy confirmed that cytotoxicity 
was proportional to the dose of free BCNU and PAA–GO–
BCNU (Figure 9). The live cells (green color) decreased 
with increasing concentration of PAA–GO–BCNU. 
  Presumably, the increased cytotoxicity of PAA–GO–BCNU 
toward GL261 cells was most likely via a combined effect 
from the increased intracellular drug concentration via 
efficient endocytosis of PAA–GO–BCNU and the improved 
drug thermal stability resulting from a decreased drug 
hydrolysis rate.
Conclusion
In summary, we have successfully functionalized nano-
sized GO with PAA to form PAA–GO which serves as an 
efficient nanocarrier for BCNU by covalent binding. Under 
the optimum condition, the nanocarrier could carry 198 µg 
BCNU/mg PAA–GO with 70% retention of drug activity. 
This nanocarrier was also demonstrated to prolong the half-
life of BCNU significantly from 19 hours to 43 hours. The 
efficient uptake of PAA–GO by cancer cells can increase 
the intracellular concentration of BCNU covalently bound 
to the nanocarrier. The in vitro anticancer efficacy of PAA–
GO–BCNU was demonstrated by a 30% increase in DNA 
interstrand cross-linking and a 77% decrease in the IC50 value 
toward GL261 cancer cells compared with the same dosage 
of free-BCNU.
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